PLx Pharma (NASDAQ:PLXP) reported quarterly losses of $(0.25) per share which missed the analyst consensus estimate of $(0.21) by 19.05 percent. This is a 32.43 percent increase over losses of $(0.37) per share from the same period last year.
Chembio Stock More Than Doubles On $28M Purchase Order For Its COVID Antigen Tests
Chembio Diagnostics Inc (NASDAQ: CEMI)